氯氮平辅助利培酮治疗难治性精神分裂症患者疗效及安全性.docVIP

氯氮平辅助利培酮治疗难治性精神分裂症患者疗效及安全性 　　【摘要】 目的 探析氯氮平辅助利培酮用于治疗难治性精神分裂症患者的疗效及安全性。 　　方法 78例难治性精神分裂症患者， 通过随机号码表法分为普通组与辅助组， 各39例。普通组采用利培酮单独药物治疗， 辅助组采用氯氮平辅助利培酮治疗。对两组患者治疗前及治疗3、6、9、12周后的阳性和阴性症状量表（PANSS）评分总分， 临床治疗效果及不良反应发生情况等进行比较。结果 治疗前， 两组PANSS评分总分比较差异无统计学意义（P0.05）；治疗3、6、9、12周后， 两组PANSS评分总分均明显低于治疗前， 且辅助组PANSS评分总分均明显低于普通组， 差异具有统计学意义（P0.05）。结论 针对难治性精神分裂症患者， 使用氯氮平辅助利培酮进行治疗， 可以在控制患者不良反应发生率的同时， 提高临床治疗效果， 是为更好的临床治疗方案。 　　【关键词】 氯氮平；利培酮；难治性精神分裂症 　　DOI：10.14163/j.cnki.11-5547/r.2018.15.008 　　Efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia patients XIANG Hong-yu， ZHANG Li. Department of Psychiatry， Chengdu Dekang Hospital， Chengdu 610091， China 　　【Abstract】 Objective To discuss and analyze the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia patients. Methods A total of 78 refractory schizophrenia patients were divided by random number table into common group and auxiliary group， with 39 cases in each group. Common group was treated with risperidone only， and auxiliary group was treated with clozapine combined with risperidone. Comparison were made on clinical treatment effect and occurrence of adverse reactions between the two groups. Results Before treatment， both groups had no positive and negative symptom scale （PANSS） score before and after 3， 6， 9 and 12 weeks， statistically significant difference in total score of PANSS score （P0.05）. After 3， 6， 9 and 12 weeks of treatment， both groups had obviously lower total PANSS score than before treatment， and auxiliary group had obviously lower total PANSS score than common group. Their difference was statistically significant （P0.05）. Conclusion Application of clozapine and risperidone for patients with refractory schizophrenia can improve the clinical treatment effect while controlling the incidence of adverse reactions. It is a better clinical treatment regimen. 　　【Key words】 Clozapine； Risperidone； Refractory schizophrenia